The price tag is over $42 billion.
Mergers & Acquisitions
Posted inMergers & Acquisitions, Oncology
Takeda Bets on Promising Gamma Delta T-cell Immunotherapy
UK-based GammaDelta Therapeutics has developed a pipeline of novel allogeneic cell therapies.
Posted inAutoimmune Diseases, Mergers & Acquisitions, Rare/Orphan Diseases
AstraZeneca + Alexion = Rescue of Both Companies
Alexion Pharmaceuticals, which owns Soliris, one of the most expensive drugs on Earth, has agreed to sell AstraZeneca for $39 billion.